How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

• Published in: British journal of pharmacology Vol. 163; no. 4; pp. 675 - 693
• Main Authors: Laverty, HG, Benson, C, Cartwright, EJ, Cross, MJ, Garland, C, Hammond, T, Holloway, C, McMahon, N, Milligan, J, Park, BK, Pirmohamed, M, Pollard, C, Radford, J, Roome, N, Sager, P, Singh, S, Suter, T, Suter, W, Trafford, A, Volders, PGA, Wallis, R, Weaver, R, York, M, Valentin, JP
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2011; Nature Publishing Group
• Subjects: adverse drug reaction; adverse event; Animals; Attrition; Bioindicators; Biological and medical sciences; Cardiovascular Agents - adverse effects; cardiovascular safety liabilities; Cardiovascular System - drug effects; Councils; drug attrition; Drug Discovery - methods; Drug Evaluation, Preclinical - methods; Drug-Related Side Effects and Adverse Reactions; Drugs; Humans; Liability; Medical research; Medical sciences; medicines; patient safety; Pharmaceutical industry; Pharmacology. Drug treatments; Reviews; Side effects; Toxicity; Human; Drug; drug attrition; patient safety; Prevalence; medicines; Toxicity; adverse event; Harmlessness; cardiovascular safety liabilities; Incidence; adverse drug reaction; Predictive value; Circulatory system

Given that cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development, adverse drug reactions, and post‐approval withdrawal of medicines, the Medical Research Council Centre for Drug Safety Science hosted a workshop to discuss current challen...